10.20.26 -- Uncovering The Biggest Risk In Scaling MSCs

Fragmented systems and manual handoffs can slow projects and obscure emerging bottlenecks. Learn how connected, automated workflows can improve coordination and strengthen project visibility.

Downstream filtration can make or break LNPs at scale. See how membrane format, loading, and shear affect recovery and stability — and how alternative TFF lowers scale‑up risk.

Advances in automated stem cell engineering are improving gene transfer efficiency while maintaining cell quality, offering a path toward safer, more standardized, and scalable manufacturing workflows.

For innovative treatments like CAR-T and stem cell transplants, optimal starting material is key. Understanding collection challenges and new solutions helps ensure the best foundation for these therapies.

Explore how Tangential Flow Depth Filtration (TFDF) enhances viral vector production, streamlining the clarification process and increasing efficiency and yield for LV and AAV manufacturing.

Plasmid DNA supply and regulatory concerns constrain large-scale viral vector manufacturing. Here, we examine whether enzymatically generated dbDNA can deliver comparable rAAV and rLV production outcomes.

Discover how multi-parameter bioprocess analyzers support monitoring of 30+ bioprocess parameters across mammalian and microbial systems to optimize yield and product quality.

Uncover how Fc engineering transforms antibodies into precise therapeutic tools by modulating immune effector functions and extending half-life to improve patient outcomes and overcome complex clinical challenges.

Take a look at manufacturing principles of LV vectors as well as testing requirement regulatory considerations with a particular focus on the replication competent virus assay and infectious titer assay.

Gain insight into how low-volume purification can be done more efficiently in GMP settings with a live system demo and customer insights on optimizing workflows with single-use chromatography.

Delve into a next-generation transfection system that requires 50% less plasmid, decreases transfection reagent consumption, and yields higher AAV productivity to reduce cost per dose.

Extracellular Vesicles (EVs) are emerging as promising natural nano-scale platforms for delivering nucleic acids, proteins, and small molecules due to their immune silencing properties.

By implementing an efficient characterization strategy, researchers can enhance the consistency of allogeneic cell therapy starting material, ultimately leading to improved clinical outcomes.

Nanoplasmids have paved the way for facilitating a wide range of cell and gene therapeutic applications. Gain an overview of a novel technology and specific benefits.

Observe a system that uses a gentle elutriation process to give manufacturers a cleaner cell population to begin cell therapy production processes such as CAR-T.